HOME >> BIOLOGY >> NEWS
The New England Journal of Medicine reports data on eculizumab for the treatment of PNH

Leeds, United Kingdom, September 21, 2006 A study led by Dr Peter Hillmen of the Leeds Teaching Hospitals NHS Trust, relating to an uncommon and severe haemolytic anaemia known as paroxysmal nocturnal haemoglobinuria (PNH), was published in the current issue of The New England Journal of Medicine. In the Phase III efficacy study, TRIUMPH, 87 patients were treated at 34 sites in the U.S., Canada, Europe, and Australia. The data showed clinically significant improvements in anaemia and the quality of life for patients with PNH.

The study was a double-blind, randomized, placebo-controlled trial that tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against complement protein C5, that inhibits terminal complement activation. Patients received either placebo or eculizumab intravenously. Eculizumab treatment significantly improved anaemia in patients as both primary endpoints were achieved, including median transfusion rate and haemoglobin stabilization over six months. The median transfusion rate was reduced from 10 units per patient with placebo to 0 units per patient with eculizumab (p<0.001). Haemoglobin stabilization was achieved by 49% of eculizumab patients as compared to 0% for placebo (p<0.001). Patients treated with eculizumab also experienced significantly less intravascular hemolysis, fatigue, pain, and shortness of breath, together with improvements in overall health status and functioning.

"PNH is a rare and life-threatening form of haemolytic anaemia where currently there are limited treatment options," said Dr. Peter Hillmen, senior author of the study, lead investigator and chairman of the TRIUMPH steering committee and Consultant Hematologist of the General Infirmary at the University of Leeds, Leeds, UK. "These study results suggest that eculizumab has great potential in providing patients diagnosed with PNH with an effective therapy."

Dr Hillmen also noted, "Patients with PNH have chro
'"/>

Contact: Greg Moulds
Greg.Moulds@leedsth.nhs.uk
1-144-113-206-6244
Euro RSCG Life NRP
21-Sep-2006


Page: 1 2

Related biology news :

1. Manomet report studies impact of massive turnover of timberland in New Englands Northern Forest
2. Data in New England Journal of Medicine show benefits of REMICADE in ulcerative colitis patients
3. Avian flu in perspective: New England Journal article reviews spectacular findings
4. Recent breakthroughs in common adult leukemia highlighted in New England Journal of Medicine
5. Stretching the supply of flu vaccine: Solution offered in new SLU research in New England Journal
6. News tips from the Journal of Neuroscience
7. News tips from the Journal of Neuroscience
8. News tips from the Journal of Neuroscience
9. News tips from the Journal of Neuroscience
10. Tips from the Journals of the American Society for Microbiology
11. Journalists can register now for ECCO 14 -- the European Cancer Conference

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2018)... ... 2018 , ... USDM Life Sciences , the leading risk management, technological ... received the 2018 Services Partner of the Year, Awarded for Innovation from Box, a ... Development and Platform Sales, Niall Wall and received by USDM Life Sciences CEO, Kevin ...
(Date:8/26/2018)... LINDA, Calif. (PRWEB) , ... August 23, 2018 ... ... the potential it has for increased sensitivity and specificity over more commonly used ... the instrumentation and the added burden of development and validation of methods that ...
(Date:8/23/2018)... (PRWEB) , ... August 22, 2018 , ... ... release of LimitLIS® 4.0, the latest version of its rapidly growing cloud-based laboratory ... LimitLIS® Toxicology Edition, as well as the company’s triple digit growth throughout 2018, ...
Breaking Biology News(10 mins):
(Date:8/31/2018)... ... August 29, 2018 , ... A recent expedition ... Southampton and the Institute of Industrial Science, the University of Tokyo, demonstrated how ... the exploration and study of hard to reach deep sea ecosystems, like intermittently ...
(Date:8/29/2018)... ... August 28, 2018 , ... Inc. Magazine ... has been ranked in 1138th place on the 27th annual Inc. 5000, the ... list represents the most successful companies within the American economy’s most dynamic segment ...
(Date:8/26/2018)... ... 23, 2018 , ... LabRoots , the leading provider ... world, will host the 4th Annual Microbiology and Immunology Virtual Event September 12-13. ... various research areas including medicine, agriculture, and space. , During the free, ...
(Date:8/21/2018)... (PRWEB) , ... August 21, ... ... a software company specializing in medical device compliance and commercialization, has just ... Cockpit® platform. , Written and presented by Dr. Mario Kossmann, ESEP at ...
Breaking Biology Technology:
Cached News: